In conclusion, this study identified GM-CSF gene expression in AML patients providing additional evidence for the possible role of that gene as a prognostic marker and indicator for treatment outcome together with already known prognostic molecular biomarkers such as CEBPA, NPM1 mut. This evidence concerns the gene CEBPA and acute myeloid leukemia.